Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
Authors
Keywords
Clinical outcome, Colon cancer, Genetic change, <em class=EmphasisTypeItalic >RAF</em>, <em class=EmphasisTypeItalic >RAS</em>
Journal
Molecular Cancer
Volume 13, Issue 1, Pages 135
Publisher
Springer Nature
Online
2014-05-31
DOI
10.1186/1476-4598-13-135
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
- (2014) Shikha Gaur et al. Molecular Cancer
- Somatic Mutations of K-Ras and BRAF in Thai Colorectal Cancer and their Prognostic Value
- (2013) Welawee Chaiyapan et al. Asian Pacific Journal of Cancer Prevention
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- (2013) George Pentheroudakis et al. BMC CANCER
- Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit
- (2013) Hideaki Bando et al. BMC CANCER
- KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
- (2013) A I Phipps et al. BRITISH JOURNAL OF CANCER
- The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
- (2013) V Eklöf et al. BRITISH JOURNAL OF CANCER
- PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer
- (2013) F. L. Day et al. CLINICAL CANCER RESEARCH
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- Aspirin and Colorectal Cancer: Back to the Future
- (2013) David Tougeron et al. CLINICAL CANCER RESEARCH
- Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
- (2013) Jean-Pierre Delord et al. EUROPEAN JOURNAL OF CANCER
- The Proto-Oncogene KRAS and BRAF Profiles and Some Clinical Characteristics in Colorectal Cancer in the Turkish Population
- (2013) Filiz Ozen et al. Genetic Testing and Molecular Biomarkers
- Tumor Heterogeneity Revealed byKRAS,BRAF, andPIK3CAPyrosequencing:KRASandPIK3CAIntratumor Mutation Profile Differences and Their Therapeutic Implications
- (2013) Vivian Kosmidou et al. HUMAN MUTATION
- Coexistent mutations ofKRASandPIK3CAaffect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
- (2013) Areumnuri Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
- (2013) Dora Colussi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features
- (2013) Christophe Rosty et al. MODERN PATHOLOGY
- miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression
- (2013) Fang-Ting Duan et al. Molecular Cancer
- The regulation of toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells
- (2013) Haiyan Guo et al. Molecular Cancer
- MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells
- (2013) Weiyun Wu et al. Molecular Cancer
- KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells
- (2013) Marzena Anna Lewandowska et al. Molecular Diagnosis & Therapy
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
- (2013) Yinchen Shen et al. PLoS One
- Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas
- (2013) Alexandre Harlé et al. VIRCHOWS ARCHIV
- Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study
- (2013) Sakarias Wangefjord et al. Biology of Sex Differences
- Epigenetics and Colorectal Cancer Pathogenesis
- (2013) Kankana Bardhan et al. Cancers
- Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
- (2012) T. André et al. ANNALS OF ONCOLOGY
- Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
- (2012) Mi-Jung Kim et al. BMC CANCER
- Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
- (2012) Ana Custodio et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction
- (2012) Sun Tian et al. GUT
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
- (2012) Mai Yamauchi et al. GUT
- The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer
- (2012) Wakkas Fadhil et al. HISTOPATHOLOGY
- KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials
- (2012) Sun Young Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines
- (2012) Isabelle Messner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
- (2012) Efsevia Vakiani et al. JOURNAL OF CLINICAL ONCOLOGY
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival
- (2012) Xiaoyun Liao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- Genome-scale analysis of aberrant DNA methylation in colorectal cancer
- (2011) T. Hinoue et al. GENOME RESEARCH
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
- (2011) A. D. Kostic et al. GENOME RESEARCH
- Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
- (2011) Karoliina Stefanius et al. HISTOPATHOLOGY
- Oncogenic PIK3CA mutations in colorectal cancers and polyps
- (2011) Vicki L.J. Whitehall et al. INTERNATIONAL JOURNAL OF CANCER
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetics and colorectal cancer
- (2011) Victoria Valinluck Lao et al. Nature Reviews Gastroenterology & Hepatology
- Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients
- (2011) Hong Shen WORLD JOURNAL OF GASTROENTEROLOGY
- KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
- (2010) Magnus Sundström et al. BMC CANCER
- A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes
- (2010) Debora Fumagalli et al. BMC CANCER
- Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
- (2010) G Smith et al. BRITISH JOURNAL OF CANCER
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
- (2010) M. Janakiraman et al. CANCER RESEARCH
- The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
- (2010) A. M. Dahlin et al. CLINICAL CANCER RESEARCH
- Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field
- (2010) S. Ogino et al. GUT
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Lifestyle Factors and Microsatellite Instability in Colorectal Cancer: The Evolving Field of Molecular Pathological Epidemiology
- (2010) S. Ogino et al. JNCI-Journal of the National Cancer Institute
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
- (2010) Irene Lurkin et al. PLoS One
- Fast simultaneous detection of K-RASmutations in colorectal cancer
- (2009) Ya-Sian Chang et al. BMC CANCER
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
- (2009) Y. He et al. CLINICAL CANCER RESEARCH
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
- (2009) Jochen Gaedcke et al. RADIOTHERAPY AND ONCOLOGY
- Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers
- (2009) Jung Ho Kim et al. VIRCHOWS ARCHIV
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
- (2008) L. Barault et al. CANCER RESEARCH
- LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
- (2008) Shuji Ogino et al. INTERNATIONAL JOURNAL OF CANCER
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started